Skip to Content

What is the difference between Cyltezo and Humira?

Medically reviewed by Last updated on Sep 16, 2019.

Official Answer


Cyltezo (adalimumab-adbm) is a biosimilar to Humira (adalimumab).

Cyltezo is not an interchangeable product with Humira; the physician must write a prescription specifically for Cyltezo.

A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Humira), and has no clinically meaningful differences in terms of safety and effectiveness.

What Are Biosimilars? Top Facts You May Not Know

Both Cyltezo and Humira belong to the class of drugs called anti-TNF-α monoclonal antibodies

Both biologics are used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. 

For more information see Comparing Cyltezo vs Humira

Related Medical Questions

Drug Information

Related Support Groups